[Empirical antibiotic therapy and ceftazidime].
Ceftazidime is indicated mainly for the empirical treatment of severe infections treated in hospital and of hospital-acquired infections. It can be used alone in numerous severe infections and it offers a good alternative to aminoglycosides and antibiotic combinations. However, there are frequent clinical situations where this drug must be used in combination with vancomycin to cover Staphylococci and Enterococci, and/or with an imidazole derivative to cover anaerobic species. Similarly, when the pathogens are known to be multiresistant the ceftazidime-aminoglycoside combination has a synergistic bactericidal activity and prevents the emergence of resistant strains. This combination is also recommended in cases where the site of infection is difficult to reach or in immunocompromised patients.
Modai
J
J
Clinique des Maladies infectieuses, Hôpital Saint-Louis, Paris.
D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002442:Ceftazidime / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000378:metabolism; D005334:Fever / Q000188:drug therapy; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D009503:Neutropenia / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002442:Ceftazidime
Antibiothérapie empirique et ceftazidime.